GLP-1 Updates
Changes to GLP-1 coverage, prices, availability and safety that affect what you can get, what you pay, or what to know before you start. Each entry says what changed, who it affects, and when, with a link to the official source and to our full guide on the topic.
Browse updates
Recent changes
-
CVS Caremark puts Zepbound back on its main employer formularies
Announced May 28, 2026 · Effective October 1, 2026
- What changed
- CVS Caremark, one of the largest pharmacy benefit managers, said it would add Zepbound back to its most common commercial formularies as an additional preferred option on October 1, 2026. It also lifted its block on Foundayo, the new GLP-1 pill, on June 1, 2026, where a plan approves it for coverage.
- Who it affects
- People whose employer or commercial plan uses a CVS Caremark formulary AND chooses to cover weight-loss medicines. Plans can still customize what they cover.
- What it means for you
- If your plan covers weight-loss GLP-1s through CVS Caremark, Zepbound may now be an option where before you were steered to Wegovy. It does not add weight-loss coverage to a plan that excludes it. Check your plan's formulary or call the number on your card.
-
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Announced August 5, 2026 · Effective October 1, 2026
- What changed
- Since October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound when they are prescribed solely for weight loss. The change comes from the state's fiscal year 2027 budget.
- Who it affects
- Rhode Island Medicaid members taking or hoping to start one of these medicines for weight loss alone. Requests for members under 21 are still reviewed for medical necessity.
- What it means for you
- If one of these medicines is medically necessary for another condition, your prescriber has to submit a new prior authorization request. Medicaid coverage of GLP-1s for type 2 diabetes is a separate federal requirement and is explained in our Medicaid guide.
Source: Rhode Island EOHHS provider memo, August 5, 2026
Checked October 8, 2026
Rhode Island Medicaid and GLP-1s → -
Mounjaro approved to lower the risk of heart attack and stroke in type 2 diabetes
Announced August 28, 2026
- What changed
- The FDA approved Mounjaro (tirzepatide) to lower the risk of major heart events (heart-related death, nonfatal heart attack or nonfatal stroke) in adults with type 2 diabetes who are at high risk for these events.
- Who it affects
- Adults with type 2 diabetes who are at high risk of these cardiovascular events. The approval is for Mounjaro, not Zepbound.
- What it means for you
- A new approved use can matter for insurance, since plans and Medicaid look at what a drug is approved for. If this describes you, it is worth raising with your prescriber.
Sources: Mounjaro prescribing information, section 1 (revised 08/2026) · Eli Lilly announcement, August 28, 2026
Checked October 8, 2026
Mounjaro guide → -
MassHealth stops covering weight-loss medicines prescribed only for weight loss
Announced March 12, 2026 · Effective July 3, 2026
- What changed
- Since July 3, 2026, MassHealth no longer covers Wegovy, Zepbound, Saxenda and the other weight-loss medicines on its list when they are prescribed only for weight loss. The change applies to every MassHealth plan type.
- Who it affects
- MassHealth members using one of these medicines for weight loss alone. Requests for members under 21 are still reviewed for medical necessity.
- What it means for you
- With prior authorization, a weight-loss GLP-1 can still be covered for established heart disease with a BMI over 27, moderate to severe sleep apnea with a BMI over 30, or MASH, and MassHealth names Wegovy as its preferred medicine for those uses. GLP-1s for type 2 diabetes fall under separate diabetes rules.
Sources: MassHealth Pharmacy Facts #271, March 12, 2026 · MassHealth Pharmacy Facts #276, May 13, 2026
Checked October 8, 2026
Massachusetts Medicaid and GLP-1s → -
Medicare starts covering some GLP-1s for weight loss at $50 a month
Announced May 6, 2026 · Effective July 1, 2026 · Ends December 31, 2027
- What changed
- A temporary program called the Medicare GLP-1 Bridge covers Foundayo, Wegovy (shot or pill) and the Zepbound KwikPen for weight loss. You pay $50 at the pharmacy for a one-month supply. It started July 1, 2026 and runs through December 31, 2027. Single-dose Zepbound vials and pens are not covered.
- Who it affects
- People 18 and older with Medicare Part D drug coverage who meet a BMI rule: 35 or higher, or 30 or 27 or higher with certain health conditions. You are not eligible if you have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, or already get a GLP-1 through your Part D plan.
- What it means for you
- If you qualify, your prescriber sends the prescription and may need to complete a prior authorization. They must also certify you are in a lifestyle program. Our Medicare guide walks through the BMI rules and the conditions that count.
-
FDA approves Foundayo, a daily GLP-1 pill for weight loss
Announced April 1, 2026
- What changed
- The FDA approved Foundayo (orforglipron), a once-daily pill from Eli Lilly, for adults with obesity, or overweight with weight-related medical problems. Lilly began shipping it through LillyDirect on April 6, 2026, with retail pharmacies following.
- Who it affects
- Adults who qualify for a weight-loss GLP-1 and would rather take a pill than an injection.
- What it means for you
- You can take it any time of day, with or without food or water. At approval, Lilly said self-pay prices start at $149 a month for the lowest dose. It is one of the medicines covered by the Medicare GLP-1 Bridge.
-
FDA approves Wegovy HD, a higher 7.2 mg dose
Announced March 19, 2026
- What changed
- The FDA approved Wegovy HD, a once-weekly 7.2 mg semaglutide shot, which is three times the standard top dose of 2.4 mg. Novo Nordisk planned a US launch in April 2026.
- Who it affects
- Adults on Wegovy, or considering it, who may need a higher dose than 2.4 mg.
- What it means for you
- NovoCare lists a self-pay price of $399 a month for Wegovy HD. Whether it suits you is a decision for your prescriber; our Wegovy guide covers what the trial found.
Sources: Novo Nordisk announcement, March 19, 2026 · NovoCare self-pay prices
Checked October 8, 2026
Wegovy guide → -
FDA says it will act against mass-marketed compounded GLP-1s
Announced February 6, 2026
- What changed
- The FDA said it would restrict the GLP-1 ingredients used in compounded drugs that companies mass-market as alternatives to approved medicines, and act against misleading ads. It said sellers may not claim a compounded drug is a generic version of, or the same as, an FDA-approved drug.
- Who it affects
- People buying compounded semaglutide or tirzepatide, often through online or telehealth programs.
- What it means for you
- Compounded GLP-1s are not FDA-approved, and the FDA cannot verify their quality, safety or effectiveness. If you use one, ask where it is made and talk to your prescriber about the approved options and their self-pay prices.
Source: FDA announcement, February 6, 2026
Checked October 8, 2026
Compounded vs brand-name GLP-1s → -
FDA asks for the suicidal thoughts warning to be removed from three GLP-1 labels
Announced January 13, 2026
- What changed
- The FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the warning about suicidal thoughts and behavior from their labels. The FDA said its review found no increased risk with GLP-1 medicines.
- Who it affects
- Anyone taking or considering Saxenda, Wegovy or Zepbound. These were the GLP-1 labels that carried the warning.
- What it means for you
- The FDA still advises: keep taking your medicine as prescribed, and contact a health care professional about new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. You can also call or text 988.
Source: FDA Drug Safety Communication, January 13, 2026
Checked October 8, 2026
Wegovy guide: side effects → -
Medi-Cal stops covering GLP-1s for weight loss
Announced November 14, 2025 · Effective January 1, 2026
- What changed
- California's Medi-Cal removed Wegovy, Zepbound and Saxenda from its drug list on January 1, 2026, and no GLP-1 is covered for weight loss after that date. Prior authorizations approved before then expired.
- Who it affects
- Medi-Cal members using a GLP-1 for weight loss. Requests for members under 21 are still reviewed for medical necessity.
- What it means for you
- Prior authorization may still be considered for Wegovy for heart disease or noncirrhotic MASH, and Zepbound for obstructive sleep apnea; a diagnosis alone does not guarantee approval. GLP-1s for type 2 diabetes are still covered under Medi-Cal's diabetes rules.
Source: Medi-Cal Rx bulletin, November 14, 2025
Checked October 8, 2026
California Medicaid and GLP-1s → -
FDA approves the Wegovy pill, the first GLP-1 pill for weight loss
Announced December 22, 2025
- What changed
- The FDA approved a once-daily Wegovy pill (oral semaglutide) for weight loss. Novo Nordisk launched it in early January 2026.
- Who it affects
- Adults who qualify for a weight-loss GLP-1 and prefer a pill to a weekly shot.
- What it means for you
- NovoCare lists self-pay prices of $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg. Unlike Foundayo, it has to be taken on an empty stomach with a short wait before eating. It is also covered by the Medicare GLP-1 Bridge.
Sources: Novo Nordisk announcement, December 22, 2025 · NovoCare self-pay prices
Checked October 8, 2026
Wegovy guide →
Coming up
-
Medicare's negotiated price for Ozempic, Rybelsus and Wegovy starts in 2027
Announced November 2025 · Effective January 1, 2027
- What changed
- Under the Medicare Drug Price Negotiation Program, CMS set a price of $274 for a 30-day supply of Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959. It takes effect January 1, 2027.
- Who it affects
- People with Medicare Part D who are prescribed one of these medicines for a use Part D covers, such as type 2 diabetes or lowering heart risk. Part D still does not cover them for weight loss alone outside the GLP-1 Bridge.
- What it means for you
- This is the price Medicare pays, not your copay. What you pay still depends on your plan, but a lower drug price can lower your share, especially if you pay a percentage of the cost.
-
Novo Nordisk cuts the list price of Wegovy and Ozempic to $675
Announced February 24, 2026 · Effective January 1, 2027
- What changed
- Starting January 1, 2027, the list price of Wegovy (2.4 mg shot and 25 mg pill), Ozempic (0.5, 1 and 2 mg) and Rybelsus (7 and 14 mg) drops to $675. Novo puts the cut at about 50% for Wegovy and 35% for Ozempic.
- Who it affects
- Mainly people with insurance whose costs are tied to the list price, such as a high-deductible plan or a plan where you pay a percentage of the price.
- What it means for you
- If you are still paying toward your deductible, or you pay coinsurance, your cost for these medicines may fall in 2027. Novo says the change does not affect its direct self-pay prices.
Source: Novo Nordisk announcement, February 24, 2026
Checked October 8, 2026
Wegovy guide: cost and savings →
Awaiting decisions
-
CagriSema is under FDA review, with a decision expected by the end of 2026
Announced December 18, 2025 · Latest update September 30, 2026
- What changed
- Novo Nordisk asked the FDA to approve CagriSema, a weekly shot that combines cagrilintide with semaglutide, for weight management. On September 30, 2026, Novo said a decision is expected in the last three months of 2026. Neither the FDA nor Novo has published a target date.
- Who it affects
- Adults with obesity, or overweight plus a weight-related condition, who are weighing whether to wait for a newer medicine.
- What it means for you
- It is not approved, so no US pharmacy can fill it, and anything sold online under that name is not legitimate. Approval would not mean instant supply or insurance coverage. Our CagriSema guide explains how it compared with Zepbound in a head-to-head trial.
-
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
Announced April 30, 2026
- What changed
- The FDA proposed leaving semaglutide, tirzepatide and liraglutide off the list of ingredients that outsourcing facilities, the large compounders, may use to make drugs from bulk ingredients. It said it found no clinical need for them to do so. This is a proposal, and the FDA says it will consider public comments before deciding.
- Who it affects
- Large compounding facilities and the people who get compounded GLP-1s made by them. The announcement addresses outsourcing facilities, not every pharmacy.
- What it means for you
- This announcement is a proposal, not a final decision. The rules that already limit compounding still apply; the FDA notes that in most cases outsourcing facilities cannot make drugs from bulk ingredients. If you rely on a compounded GLP-1, it is worth knowing what the approved options cost.
How we choose what goes here
An update earns a place if it changes what you can access, what you pay, or what you need to know before seeking treatment. That covers insurance and Medicare or Medicaid coverage, manufacturer prices and savings programs, FDA approvals and new forms of a drug, official FDA safety communications, and major FDA review milestones. We leave out stock market news, celebrity stories and single studies.
We cite the official source for every entry: the FDA, CMS, a state Medicaid agency, or the drug maker. When an offer ends or a policy is replaced, the entry stays here and its label changes, so you can see what used to apply. Nothing on this page is medical advice. Spot an error? See our corrections policy.
Find GLP-1 clinics near you
Coverage and prices keep changing, and clinics can tell you what applies to you today. Tell us your state. We’ll review your request before sharing your details with selected clinics, so they can get in touch.